Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. car art

CAR ART SIGNED

Chimeric Antigen Receptor to generate Alloantigen-specific Regulatory T cells and promote allograft tolerance

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CAR ART project word cloud

Explore the words cloud of the CAR ART project. It provides you a very rough idea of what is the project "CAR ART" about.

canada    survival    immunologists    car    fellowship    levings    immunosuppressive    treatment    cellular    graft    limitation    outgoing    relies    risk    allograft    successfully    france    chimeric    cd4foxp3    return    human    donor    transplant    models    limited    experimental    alloimmune    vancouver    clinic    infections    antigen    clinical    expanded    supporting    humoral    alloantigens    transfer    cellulaire    immune    overcome    organ    terminal    alloantigen    generate    hindered    culaire    trial    drugs    valbonne    receptor    cells    glaichenhaus    indicated    life    adoptive    cancers    transplantation    institut    toward    induction    preclinical    applicable    strategies    treg    few    translation    de    ing    clinically    redirect    potency    researcher    lack    kidney    family    team    tenured    grail    performed    et    mol    vivo    ex    lab    pharmacologie    morbidity    markedly    global    prevention    pr    specificity    destructive    tregs    data    potent    therapy    action    position    group    child    indefinite    sufficient    ambition    regulatory    eacute    tolerance    recipient    rejection    enhanced   

Project "CAR ART" data sheet

The following table provides information about the project.

Coordinator		 CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS 

Organization address
address: RUE MICHEL ANGE 3
city: PARIS
postcode: 75794
website: www.cnrs.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country France [FR]
 Total cost 171˙349 €
 EC max contribution 171˙349 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2016
 Funding Scheme MSCA-IF-GF
 Starting year 2017
 Duration (year-month-day) from 2017-11-01   to  2019-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS FR (PARIS) coordinator 171˙349.00
2    UNIVERSITY OF BRITISH COLUMBIA CA (VANCOUVER) partner 0.00

Map

 Project objective

Organ transplantation is the best life-supporting treatment for terminal organ failure. Graft survival is however limited by rejection, a destructive process resulting from the response of recipient’s immune system against donor specific alloantigens. Prevention of rejection currently relies on immunosuppressive drugs that lack antigen specificity and therefore increase the risk for infections and cancers. Induction of donor-specific tolerance would provide indefinite graft survival without morbidity and therefore represents the Grail of transplant immunologists. Tolerance has been obtained in experimental models with adoptive transfer of ex vivo-expanded CD4FOXP3 regulatory T cells (Treg). Preclinical studies have indicated that the potency and specificity of Treg therapy could be markedly enhanced by the use of Treg specific for donor alloantigens. Translation of this approach in the clinic has been hindered by the lack of clinically applicable strategies to generate sufficient numbers of potent donor-specific Tregs. To overcome this limitation, Pr Levings’ group (Child and Family Research Institute, Vancouver, Canada) has just recently successfully used chimeric antigen receptor (CAR) technology to redirect the specificity of human Treg toward a transplant-relevant antigen. The objective of the 2-year action is to assess the impact of alloantigen-specific CAR Treg on cellular and humoral alloimmune responses and their ability to promote allograft tolerance. The outgoing phase of the global fellowship will be performed in Pr Levings’ lab, and the return phase in Pr Glaichenhaus’ team (Institut de Pharmacologie Moléculaire et Cellulaire, Valbonne, France) where the researcher will get in few years a tenured position. The main ambition of the program is to provide key data for the development of a clinical trial with CAR Tregs in kidney transplantation.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CAR ART" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CAR ART" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

GrowthDevStability (2020)

Characterization of the developmental mechanisms ensuring a robust symmetrical growth in the bilateral model organism Drosophila melanogaster

Read More  

NarrowbandSSL (2019)

Development of Narrow Band Blue and Red Emitting Macromolecules for Solution-Processed Solid State Lighting Devices

Read More  

RipGEESE (2020)

Identifying the ripples of gene regulation evolution in the evolution of gene sequences to determine when animal nervous systems evolved

Read More